Skip to main content

Overview

Bradley B. Pua, M.D. is Chief of the Division of  Interventional Radiology and Director of the Lung Screening Program at New York Presbyterian Weill Cornell Medicine.

Dr. Pua obtained a B.S. degree in Chemistry from New York University (NYU) and continued at NYU School of Medicine where he was awarded his M.D. degree. He completed three years of surgical residency at New York University Medical Center prior to deciding to pursue a career in Interventional Radiology and subsequently completed a fellowship in Interventional Radiology at NewYork-Presbyterian Hospital-Weill Cornell Campus & Memorial Sloan Kettering Cancer Center. Dr. Pua remained at Cornell to complete his diagnostic radiology residency and was elected to serve as Chief Resident in his final year.

Dr. Pua's clinical expertise is in Interventional Radiology and performs a variety of interventional procedures including, but not limited to: arterial embolizations, stent placements, tumor ablations, biopsies and vascular access. His interests include both pediatric interventions and minimally invasive cancer therapy, with a particular focus on thoracic tumors.

Dr. Pua's research interests are in simulators for medical education as well as thoracic tumor treatments for which he has written both review articles and book chapters.

Dr. Pua is a reviewer for the Radiology, Journal of Vascular and Interventional Radiology, Clinical Imaging and Journal of Translational Lung Cancer Research.

Top Procedures:

1. Embolization and ablation of various tumors.

2. Pediatric Interventions

3. Management of Vascular Malformations

4. Image Guided Biopsy

Highlights

  1. 1
    Journal of the American College of Radiology : JACR · 2023
    PMID: 37984766DOIFirst author22 citations
  2. 2
    Journal of the American College of Radiology : JACR · 2023
    PMID: 37422161DOISenior author2 citations
  3. 3
    Clinical lung cancer · 2025
    PMID: 39890572DOISenior author

Publications

81 publications

Funding

6 grants

Active

2 grants
  • Co-I
    The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials Network
    National Cancer Institute · 2021–2027 · via The Ohio State University· 2 renewals
    UM1CA186712-07
  • Co-I
    Federated Ecosystem for Analytics and Standardization Technologies. FEAST
    ARPA-H · 2024–2026 · via DNA Hive, LLC
    FEAST-ORG-002
Completed grants (4)
  • PI
    Service Agreement for Study: GVI-1028 HBV Vaccination of Healthy Volunteers to Evaluate the Composition of Germinal Centers
    Rockefeller University · 2022–2023Contract
    RU 224881-01
  • MPI
    CASTL: Cessation and Screening to Save Lives
    National Cancer Institute · 2018–2023 · via Sloan-Kettering Institute for Cancer Research
    R01CA207442-01
  • Co-I
    Molecular and cellular profiling of preinvasive and minimally invasive lesions to understand the biology underlying progression from indolent to more invasive tumors
    Johnson & Johnson · 2020–2022
    J&J Biopharma 213315-02
  • KP
    Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
    National Heart, Lung, and Blood Institute · 2011–2016 · via Washington University, The
    U01HL088476-05

Clinical research

6 studies

Active

1 study
  • PI
    Clinical Evaluation of an Intra-procedural 3D Needle Guidance Platform for Soft Tissue Tumors or Organs Requiring Percutaneous Biopsy as an Adjunct to Standard Image Guidance
    NA · MediView XR · OPEN TO ACCRUAL (as of 2025)
    Oncology; Interventional Radiology; Liver Carcinoma; Renal Carcinoma; Biopsy
    NCT07046832
Completed & closed trials (5)
  • PI
    Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites
    PHASE4 · Memorial Sloan Kettering Cancer Center · IRB STUDY CLOSURE (as of 2026)
    Smoking Cessation
    NCT03315910
  • PI
    A Pilot Study to Evaluate Mobile Low-dose Computed Tomography Lung Cancer Screening Implementation in an Urban Setting.
    Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2025)
  • PI
    Use of Virtual Reality/Augmented Reality device for students and practitioners in an Interventional Radiology setting
    Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2025)
  • PI
    A Clinical Study of Aliya™ Pulsed Electric Fields (PEF) Delivered Prior to Standard of Care Treatment for Advanced Cancer
    NA · Galvanize Therapeutics, Inc. · CLOSED TO ACCRUAL (as of 2024)
    Lung Neoplasm Malignant
    NCT05890872
  • PI
    Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites
    PHASE4 · Memorial Sloan Kettering Cancer Center · IRB STUDY CLOSURE (as of 2021)
    Smoking Cessation
    NCT03315910

News mentions

External relationships

Advisory/Scientific Board Member

DNA Hive, LLC · Galvanize Therapeutics, Inc. · GE Healthcare · MediView XR

Proprietary Interest

Oxford University Press Inc.

Other

Galvanize Therapeutics, Inc. · GE Healthcare · MediView XR